Special Issue "NF-kappaB signalling pathway"

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: 31 May 2019

Special Issue Editor

Guest Editor
Prof. Dr. Alexander Arlt

Laboratory of Molecular Gastroenterology & Hepatology, Department of Internal Medicine I, UKSH-Campus Kiel, 24105 Kiel, Germany
Website | E-Mail
Interests: NF-kappaB; cell death; pancreatic cancer; inflammation

Special Issue Information

Dear Colleagues,

This Special Issue is about the NF-kappaB signalling pathway and its pleiotropic effects on different aspects of cancer, including oncogenesis and therapy resistance. Originally described in the context of inflammation, a huge amount of excellent work has been done to describe the role of NF-kappab as a central tumor-promoting signalling pathway in inflammation-associated cancer. Furthermore, components of the pathway and the NF-kappab subunits itself are frequently genetically altered in tumors. In addition, emerging data demonstrate that NF-kappab signalling is involved in different aspects of therapy resistance. In addition to the tumor cell-intrinsic function, this signalling pathway has been shown to be crucial in mediating onco-immuno signalling and in the regulation of the tumor microenvironment of several tumor entities. Furthermore, NF-kappaB is involved in aspects like metabolism, immunity, epigenetic regulation, and all kinds of cell deaths, predestining this signalling pathway to be one of the most attractive molecular targets in cancer therapy. However, some very eloquent publications have raised the issue that under certain conditions NF-kappaB can act as a direct tumor suppressor and also mediate anti-tumor immune responses, presenting a dilemma when designing NF-kappaB targeting anti-tumor therapies.

Here, we welcome papers outlining the recent anti- but also the pro-tumorigenic role of NF-kappaB.

Prof. Dr. Alexander Arlt
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers

This special issue is now open for submission.
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top